KR101995302B1 - 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 - Google Patents

조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 Download PDF

Info

Publication number
KR101995302B1
KR101995302B1 KR1020137028821A KR20137028821A KR101995302B1 KR 101995302 B1 KR101995302 B1 KR 101995302B1 KR 1020137028821 A KR1020137028821 A KR 1020137028821A KR 20137028821 A KR20137028821 A KR 20137028821A KR 101995302 B1 KR101995302 B1 KR 101995302B1
Authority
KR
South Korea
Prior art keywords
seq
monoclonal antibody
residue
ser
tfpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137028821A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019428A (ko
Inventor
쯔오즈시 왕
존 머피
토비아스 마르쿠아르트
디터 모스마이어
Original Assignee
바이엘 헬스케어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101995302(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 헬스케어 엘엘씨 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20140019428A publication Critical patent/KR20140019428A/ko
Application granted granted Critical
Publication of KR101995302B1 publication Critical patent/KR101995302B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137028821A 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 Expired - Fee Related KR101995302B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
US61/471,101 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018445A Division KR20190079698A (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Publications (2)

Publication Number Publication Date
KR20140019428A KR20140019428A (ko) 2014-02-14
KR101995302B1 true KR101995302B1 (ko) 2019-07-02

Family

ID=46932389

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137028821A Expired - Fee Related KR101995302B1 (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체
KR1020197018445A Ceased KR20190079698A (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197018445A Ceased KR20190079698A (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Country Status (37)

Country Link
US (5) US20140294832A1 (https=)
EP (1) EP2694544B1 (https=)
JP (4) JP6170903B2 (https=)
KR (2) KR101995302B1 (https=)
CN (2) CN103797030B (https=)
AU (3) AU2012236296A1 (https=)
BR (1) BR112013025376A2 (https=)
CA (2) CA2831907C (https=)
CL (1) CL2013002811A1 (https=)
CO (1) CO6890074A2 (https=)
CR (1) CR20130499A (https=)
CU (1) CU20130128A7 (https=)
CY (1) CY1121538T1 (https=)
DK (1) DK2694544T3 (https=)
DO (1) DOP2013000218A (https=)
EA (2) EA034214B1 (https=)
EC (1) ECSP13012913A (https=)
ES (1) ES2722824T3 (https=)
GT (1) GT201300229A (https=)
HK (1) HK1243426A1 (https=)
HR (1) HRP20190467T1 (https=)
HU (1) HUE042706T2 (https=)
IL (4) IL228633B (https=)
LT (1) LT2694544T (https=)
MX (1) MX2013011218A (https=)
MY (2) MY165499A (https=)
PE (1) PE20141149A1 (https=)
PH (4) PH12013502039B1 (https=)
PL (1) PL2694544T3 (https=)
PT (1) PT2694544T (https=)
RS (1) RS58633B1 (https=)
SG (2) SG10201602606UA (https=)
SI (1) SI2694544T1 (https=)
TR (1) TR201905101T4 (https=)
UA (1) UA113623C2 (https=)
WO (1) WO2012135671A2 (https=)
ZA (1) ZA201308169B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
EP2379600B2 (en) † 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
PE20141149A1 (es) * 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
CN104185474B (zh) 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6586016B2 (ja) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
PL2970497T3 (pl) 2013-03-15 2018-05-30 Bayer Healthcare Llc Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) * 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017196A2 (en) * 2008-08-04 2010-02-11 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
HUE047173T2 (hu) * 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
PE20141149A1 (es) * 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017196A2 (en) * 2008-08-04 2010-02-11 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor

Also Published As

Publication number Publication date
AU2019201814A1 (en) 2019-04-04
SG193594A1 (en) 2013-10-30
EP2694544A4 (en) 2015-03-25
PH12013502039A1 (en) 2013-12-16
CN107090046A (zh) 2017-08-25
BR112013025376A2 (pt) 2017-07-25
ZA201308169B (en) 2016-03-30
PH12019500441A1 (en) 2020-10-12
JP6170903B2 (ja) 2017-07-26
EP2694544B1 (en) 2019-01-23
AU2017203105A1 (en) 2017-06-01
US20220041752A1 (en) 2022-02-10
IL274686B (en) 2021-09-30
JP2017113019A (ja) 2017-06-29
CA2831907A1 (en) 2012-10-04
PH12019500439A1 (en) 2020-10-12
JP6363747B2 (ja) 2018-07-25
PL2694544T3 (pl) 2019-07-31
KR20190079698A (ko) 2019-07-05
JP2018172411A (ja) 2018-11-08
CL2013002811A1 (es) 2014-02-28
EA034214B1 (ru) 2020-01-17
AU2012236296A1 (en) 2013-10-24
CA3068997A1 (en) 2012-10-04
PE20141149A1 (es) 2014-08-28
SG10201602606UA (en) 2016-04-28
IL283829A (en) 2021-07-29
EP2694544A2 (en) 2014-02-12
US20140294832A1 (en) 2014-10-02
MX2013011218A (es) 2013-10-17
CO6890074A2 (es) 2014-03-10
CN103797030A (zh) 2014-05-14
ES2722824T3 (es) 2019-08-19
IL257145A (en) 2018-03-29
HRP20190467T1 (hr) 2019-05-03
DK2694544T3 (en) 2019-04-15
CY1121538T1 (el) 2020-05-29
EA201991704A2 (ru) 2020-03-31
IL228633B (en) 2018-03-29
NZ615969A (en) 2016-01-29
JP2014511685A (ja) 2014-05-19
RS58633B1 (sr) 2019-05-31
DOP2013000218A (es) 2013-11-15
KR20140019428A (ko) 2014-02-14
US20190194353A1 (en) 2019-06-27
ECSP13012913A (es) 2014-02-28
CA2831907C (en) 2020-03-24
HK1243426A1 (zh) 2018-07-13
MY165499A (en) 2018-03-27
GT201300229A (es) 2014-11-13
TR201905101T4 (tr) 2019-05-21
IL274686A (en) 2020-06-30
CU20130128A7 (es) 2014-03-26
CR20130499A (es) 2013-10-24
EA201991704A3 (ru) 2020-06-30
EA201301107A1 (ru) 2014-11-28
IL228633A0 (en) 2013-12-31
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
HUE042706T2 (hu) 2019-07-29
JP2021019619A (ja) 2021-02-18
US20170107298A1 (en) 2017-04-20
WO2012135671A3 (en) 2012-12-13
SI2694544T1 (sl) 2019-06-28
PH12013502039B1 (en) 2013-12-16
US20180194857A1 (en) 2018-07-12
PT2694544T (pt) 2019-04-02
CN103797030B (zh) 2017-05-31
LT2694544T (lt) 2019-04-25
WO2012135671A2 (en) 2012-10-04
UA113623C2 (uk) 2017-02-27

Similar Documents

Publication Publication Date Title
KR101995302B1 (ko) 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체
KR101974980B1 (ko) 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202745B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK1197829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829B (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ615969B2 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220627

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220627